Press releases
- Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
- Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
- Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
- Biohaven Announces Proposed Public Offering of Common Shares
- Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
More ▼
Key statistics
On Wednesday, Biohaven Ltd (ZH6:BER) closed at 31.20, 43.22% above the 52 week low of 21.79 set on Oct 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 31.80 |
---|---|
High | 32.20 |
Low | 30.00 |
Bid | 29.60 |
Offer | 33.00 |
Previous close | 31.60 |
Average volume | 4.44 |
---|---|
Shares outstanding | 88.29m |
Free float | 72.29m |
P/E (TTM) | -- |
Market cap | 3.02bn USD |
EPS (TTM) | -6.83 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 19:21 BST.
More ▼